Clinical Trial

Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

Study acronym: NeoHTerMa
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The aim of this study is to investigate whether the application of concomitant modulated electro-hyperthermia in a neoadjuvant chemotherapeutic setting is beneficial for patients with HER2-negative, stage II-III breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-25; most recent amendment 2026-05-12.
Status change: Recruiting → Active, Not Recruiting 2024-11-27
Trial Details
NCT Number NCT05889390
Lead Sponsor Semmelweis University
Conditions HER2-negative Breast Cancer
Enrollment 71 participants
Start Date 2023-02-20
Primary Completion 2025-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-15